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Background: Tyrosine phosphorylation of PKM2 inhibits its activity; however, the phosphatase(s) that regulates PKM2
phosphorylation remains unidentified.
Results: PKM2 is a novel PTP1B substrate and PKM2 Tyr-105 and Tyr-148 are key sites that mediate the interaction.
Conclusion: PTP1B regulates PKM2 tyrosine phosphorylation and activity in adipocytes.
Significance: These findings provide new insights into the regulation of adipose PKM2 activity.
Protein-tyrosine phosphatase 1B (PTP1B) is a physiological
regulator of glucose homeostasis and adiposity and is a drug
target for the treatment of obesity anddiabetes.Herewe identify
pyruvate kinase M2 (PKM2) as a novel PTP1B substrate in adi-
pocytes. PTP1B deficiency leads to increased PKM2 total tyro-
sine and Tyr105 phosphorylation in cultured adipocytes and in
vivo. Substrate trapping andmutagenesis studies identify PKM2
Tyr-105 and Tyr-148 as key sites that mediate PTP1B-PKM2
interaction. In addition, in vitro analyses illustrate a direct effect
of Tyr-105 phosphorylation on PKM2 activity in adipocytes.
Importantly, PTP1B pharmacological inhibition increased
PKM2 Tyr-105 phosphorylation and decreased PKM2 activity.
Moreover, PKM2 Tyr-105 phosphorylation is regulated nutri-
tionally, decreasing in adipose tissue depots after high-fat feed-
ing. Further, decreased PKM2 Tyr-105 phosphorylation corre-
lates with the development of glucose intolerance and insulin
resistance in rodents, non-human primates, and humans.
Together, these findings identify PKM2 as a novel substrate of
PTP1B and provide new insights into the regulation of adipose
PKM2 activity.
The obesity epidemic and its associated comorbidities,
including type 2 diabetes, cardiovascular disease, and many
cancers, have increased interest in adipose tissue metabolism
because this may present a novel therapeutic target (1). The
adipose tissue integrates an array of homeostatic processes and
is an important regulator of systemic insulin sensitivity and
energy metabolism (2). There are two major types of adipose
tissues in mammals: white and brown. White adipose tissue is
the primary site for triglyceride storage or fatty acid release,
whereas brown adipose tissue (BAT)4 is a thermogenic tissue
with an established role in the defense against cold and emerg-
ing antiobesity properties (3, 4). Genetic and molecular studies
identify tyrosine phosphorylation as a regulator of adipose tis-
sue function, systemic glucose homeostasis, and energy balance
(5–9).
Tyrosine phosphorylation is tightly controlled by the oppos-
ing actions of protein tyrosine kinases and protein tyrosine
phosphatases (PTPs) (10). Protein tyrosine phosphatase 1B
(PTP1B) is a ubiquitously expressed non-receptor tyrosine-
specific phosphatase that is localized on the cytoplasmic face of
the endoplasmic reticulum (11–13). PTP1B is a physiological
regulator of glucose homeostasis and energy balance. Specifi-
cally, whole-bodyPTP1BKOmice are hypersensitive to insulin,
lean, and resistant to high-fat diet (HFD)-induced obesity (14,
15). Mice with tissue-specific PTP1B deletion in the liver and
muscle exhibit improved glucose homeostasis independent of
body weight (16–18), whereas mice with neuronal deletion
exhibit decreased bodyweight (19).However, the role of PTP1B
in adipocytes is unresolved, with studies demonstrating detri-
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mental or beneficial effects of adipose PTP1B deficiency on
body mass and insulin sensitivity (19, 20). Notably, PTP1B is a
modulator of brown fat adipogenesis through a peroxisome
proliferator-activated receptor -dependent mechanism, and
PTP1B deficiency regulates PKR-like endoplasmic reticulum-
regulated kinase phosphorylation and protein synthesis (21–
23). Collectively, the salutary effects of PTP1B deficiency on
obesity and diabetes have focused attention on it as a potential
therapeutic target.
Pyruvate kinase (PK), a rate-limiting glycolytic enzyme, cat-
alyzes the generation of pyruvate and ATP from phosphoenol-
pyruvate and ADP (24). In mammals, four pyruvate kinase iso-
forms exist: the L and R isoforms of the PKLR gene are
expressed in liver and erythrocytes, respectively; the M1 splice
isoformof the PKMgene is characteristic ofmore differentiated
adult cells (e.g. muscle and brain); and the M2 isoform is
expressed during embryonic development and in proliferative
adult cell types (25). PKM2expression facilitates aerobic glycol-
ysis in tumors and provides a growth advantage (26, 27). Of
note, tyrosine phosphorylation inhibits PKM2 activity (28).
However, the phosphatase(s) that regulate(s) PKM2 remain(s)
unidentified. In this study, we identify PKM2 as a novel PTP1B
substrate and provide new insights into the regulation of adi-
pose PKM2 activity.
EXPERIMENTAL PROCEDURES
Reagents—DMEM, G418, penicillin/streptomycin, puromy-
cin, newborn calf serum, FBS, and trypsin were purchased from
Invitrogen. PTP1B pharmacological inhibitor (compound II,
CII) was prepared as described (29). Antibodies for human
PTP1B (FG6), mouse PTP1B, and PKM1/2 were purchased
from Abcam (Cambridge, MA). Tubulin antibodies were pur-
chased from Upstate Biotechnology (Lake Placid, NY). PKM1
antibodies were purchased from Sigma. pPKM2 (Tyr-105),
PKM2, pAKT (Ser-473), AKT, and FLAG antibodies were pur-
chased from Cell Signaling Technology (Beverly, MA). pIR
(Tyr-1162/Tyr-1163), and IR antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). HRP-conjugated
secondary antibodieswere purchased fromBioResources Inter-
national (Carlsbad, CA). Unless indicated otherwise, chemicals
were purchased from Sigma.
Cell Culture—Brown adipose cell lines were generated from
whole-body PTP1B KO mice and reconstituted with human
PTP1B WT and substrate-trapping mutant (D181A) as
described previously (21). 3T3-L1 cells were maintained in
DMEMcontaining 25mM glucose, 10% newborn calf serum, 50
units/ml penicillin, and 50g/ml streptomycin. PKM silencing
in 3T3-L1 cells was achieved by testing three different hairpins
(Open Biosystems). Because the hairpins target regions that are
shared for mouse PKM1 and PKM2, expression of both pro-
teins was evaluated with one shRNA yielding a significant
decrease in PKM2 without significant alterations in PKM1.
Packaging (psPAX2) and envelope (pMD2.G) vectors were
obtained from Addgene (Boston, MA). Lentiviruses were gen-
erated by cotransfection of vectors in HEK293FT cells using
Lipofectamine 2000 (Invitrogen) following the guidelines of the
manufacturer and then used to infect 3T3-L1 cells. Cells were
selected using puromycin (2 g/ml), and drug-resistant pools
were propagated. Knockdown cells were reconstituted by tran-
sient transfection of PKM2 WT or mutants. Stable cell lines
were selected using G418 at a concentration of 400 g/ml.
To induce cell differentiation, brown and 3T3-L1 preadi-
pocytes were grown to confluence in culture medium contain-
ing 10% FBS or 10% newborn calf serum, respectively. Conflu-
ent cells were then switched to differentiation medium
containing 20% FBS, 20 nM insulin, and 1 nM triiodothyronine
(T3) for 48 h. Adipocyte differentiation was induced by incu-
bating cells for 48 h in differentiation medium further supple-
mented with 5 M dexamethasone, 0.5 mM isobutylmethylxan-
thine, and 0.125 mM indomethacin (induction medium). After
induction, cells were cultured in differentiation medium until
they exhibited a differentiated phenotype with accumulation of
fat droplets. For confocal microscopy, cells were grown on cov-
erslips and fixed with 100% ice-cold methanol for 10 min and
then blocked with 3% BSA in PBS for 60 min. After incubation
with primary antibodies and fluorescent-conjugated secondary
antibodies, cells were mounted in Mowiol (Sigma) and exam-
ined using Olympus FluoView laser-scanning confocal micros-
copy. Adipose tissue from different fat pads were fixed in 10%
formalin and embedded in paraffin. Sectionswere stained using
PKM2 and pPKM2 (Tyr-105) antibodies. Detection of protein
specific bands was performed with appropriate fluorescein-
conjugated secondary antibodies and visualized using a Leica
DMI3000B inverted microscope.
Biochemical Analyses—Tissues/cells were homogenized in
radioimmunoprecipitation assay buffer. Lysates were clarified
by centrifugation at 13,000 rpm for 10 min, and protein con-
centrations were determined using a bicinchoninic acid assay
kit (Pierce Chemical). Proteins (30–90 g) were resolved by
SDS-PAGE and transferred to PVDF membranes. For sub-
strate-trapping experiments, cells were lysed in 1% Nonidet
P-40 buffer with a protease inhibitor mixture (without sodium
orthovanadate). Immune complexes were collected on Pure-
Proteome beads (Millipore) and washed with lysis buffer.
Immunoblotting of lysates was performed with primary anti-
bodies, and after incubation with secondary antibodies, pro-
teins were visualized using enhanced chemiluminescence
(Amersham Biosciences). Pixel intensities of immunoreactive
bands were quantified using FluorChem Q imaging software
(Alpha Innotech).
For site-directed mutagenesis, the indicated tyrosine (Y) to
phenylalanine (F) mutations in mouse PKM2 cDNA were gen-
erated using a QuikChange Lightning site-directed mutagene-
sis kit (Agilent) following the instructions of the manufacturer
and confirmed by DNA sequence analysis.
PTP1B Enzymatic Activity—3T3-L1 preadipocytes were
treated with PTP1B inhibitor (compound II, 200 nM) (29) for
12 h and then lysed in Nonidet P-40 buffer (10 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 5%
glycerol, and proteases inhibitors). 1 mg of total protein lysates
was used to immunoprecipitate PTP1B using PureProteome
beads (Millipore). The precipitate was washed twice with ice-
cold lysis buffer and then resuspended in 50 l of reaction
buffer (50 mMHEPES (pH 5.0), 1 mM EDTA, 100 mMNaCl and
5 mM DTT) for 10 min, and the reaction was initiated by the
addition of p-nitrophenyl phosphate (5 mM). PTP1B activity
PTP1B Regulates PKM2 Tyrosine Phosphorylation
JUNE 14, 2013•VOLUME 288•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 17361
 at U
niversity of California, D
avis on January 24, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
was monitored by measuring the absorbance of p-nitrophenyl
phosphate at 405 nm using a Wallac Victor 2 plate reader
(PerkinElmer Life Sciences, Waltham, MA).
Measurement of Total Pyruvate Kinase Activity—Cells were
lysed in 10 mM Tris-HCl (pH 7.5), 1.5 mMMgCl2, 20 mM NaCl,
1mMDTT, 1mMPMSF, and a protease inhibitormixture, incu-
bated on ice for 20 min, and lysed with a glass Dounce homog-
enizer. Cell debris and unbroken cells were removed by centrif-
ugation at 10,000 rpm for 15 min, and total pyruvate kinase
activity was measured in the supernatant by a lactate dehydro-
genase-coupled assay as described previously (30) with modifi-
cations. Briefly, proteins (1g) were added to 200l of reaction
buffer containing 100 mM Tris-HCl (pH 8.0), 100 mM KCl, 10
mM MgCl2, 0.5 mM EDTA, 0.2 mM -NADH, 1.5 mM ADP, 5
mM phosphoenolpyruvate, and 0.6 units/ml lactate dehydro-
genase. Pyruvate kinase activity was calculated at 25 °C bymon-
itoring the absorbance at 340 nm using a Wallac Victor 2 plate
reader. To determine the effects of PTP1B inhibition on pyru-
vate kinase activity cells were pretreated with CII for 12 h, and
then pyruvate kinase activity was determined as described. CII
was added to the lysis and reaction buffers.
LC-MS/MS Mass Spectrometry—Brown preadipocytes were
cultured and differentiated as indicated. Adipocytes were
homogenized inNonidet P-40 buffer (10mMTris-HCl (pH7.4),
150mMNaCl, 1% IGEPALTMCA-630, and protease inhibitors).
Lysates were clarified by centrifugation at 13,000 rpm for 10
min, and protein concentrations were determined using a
bicinchoninic acid assay kit (Pierce Chemical). Proteins were
resolved by SDS-PAGE, and gels were stained using Coomassie
Brilliant Blue. Then, the 60- and 160-kDa bands were excised
and processed by in-gel trypsin digestion to generate tryptic
peptides. Tryptic peptides were resolved by reverse-phase
chromatography (Cys-18) on an integrated nano-LC system
(Easy-nLC, ProxeonBiosystems) and analyzed on aLinearQua-
drupole ION Trap/Finnigan Polaris Q Mass Spectrometer
(Thermo Scientific). Tandem mass spectra were extracted
using ReadW.exe in centroid mode and searched with X!Tan-
dem using the international protein index. Scaffold (Proteome
Software) was used to validate MS/MS-based peptide and pro-
tein identifications as described previously (31).
Mouse Studies—C57Bl/6J (The Jackson Laboratory) male
mice were maintained on a 12-hour light-dark cycle and fed ad
libitum. Mice were fed standard lab chow (Purina Lab Chow,
catalog no. 5001) or switched to a HFD (60% kcal from fat,
catalog no. D12492, Research Diets) at 7 weeks of age. PTP1B-
floxed (PTP1B fl/fl) mice were generated previously (19). Adi-
ponectin-Cre mice were obtained from Dr. E. Rosen (Beth
Israel Deaconess Medical Center/Harvard University). Geno-
typing for the PTP1B floxed allele and presence of Cre was
performed by PCR using DNA extracted from tails as described
(19). At the indicated age, mice were sacrificed, and different
adipose depots were collected, frozen in liquid nitrogen, and
then stored at 80 °C. Mouse studies were approved by Insti-
tutional Animal Care and Use Committee at the University of
California Davis.
Human and Non-human Primate Studies—Rhesus monkeys
(9–17 years old) provided by the California National Primate
Research Center were maintained at the California National
Primate Research Center at the University of California Davis.
Monkeys were provided 500 ml/day of a fruit-flavored (Kool-
Aid, Kraft Foods, Northfield, IL), 15% fructose-sweetened bev-
erage (75 g of fructose) for 6 months or fed fructose supple-
mentedwith fish oil (fish oil, 4 g/day: 18% eicosapentaenoic acid
and 12%docosahexaenoic acidOmega-3) for 6months.Human
subjects (40–72 years, body mass index 25–35 kg/m2) were
recruited for a 12-week study on the basis of the following
exclusion criteria: evidence of diabetes, renal or hepatic disease,
fasting serum triglyceride concentrations  400 mg/dl, blood
pressure 140/90mmHg, and surgery for weight loss. Subjects
consumed diets designed tomaintain energy balance providing
15% of energy as protein, 30% as fat, and 55% as carbohydrate.
Daily energy intake was calculated at base line using theMifflin
equation to estimate resting energy expenditure and adjusted
for activity using a multiplication factor of 1.5. For the first
2-week inpatient base-line period, the carbohydrate content
consisted primarily of complex carbohydrates and contained
8.8  1.2 g of dietary fiber/1000 kcal. During the following 8
outpatient weeks of the study, subjects lived at home and con-
sumed glucose or fructose beverageswith their usual ad libitum
diets. For the final 2-week inpatient intervention period, sub-
jects consumed diets at the base-line energy level and macro-
nutrient composition, except that 30% of the energy was from
complex carbohydrates and 25% was provided by fructose- or
glucose-sweetened beverages. The study was approved by the
University of California Davis Institutional Review Board, and
subjects provided informed consent to participate.
Statistical Analyses—Data are expressed asmeans S.E. Sta-
tistical analyses were performed using the JMP program (SAS
Institute). Comparisons between groups were performed using
unpaired two-tailed Student’s t test. *, p 0.05; **, p 0.01.
RESULTS
Identification of Adipose PTP1B Substrates—To gain insight
into the molecular mechanisms underlying PTP1B action, we
utilized substrate-trapping and mass spectroscopy approaches
to identify novel adipose PTP1B substrates. PTP1B WT has a
high catalytic constant (32), rendering its interaction with sub-
strates transient and difficult to detect. However, the steady-
state interaction of PTP1Bwith its substrates is enhanced in the
substrate-trapping PTP1B mutant D181A (D/A) that retains
substrate binding but is catalytically impaired (33). Thus,
PTP1B D/A forms stable complexes with tyrosine-phosphory-
lated substrates. The substrate-trapping approach has been uti-
lized successfully to identify PTP1B substrates (13, 22, 33–35).
Brown preadipocyte cell lines were generated from PTP1B KO
mice and reconstituted with PTP1B D/A as described previ-
ously (21). PTP1B was immunoprecipitated from starved or
insulin-stimulated (10 and 30 min) PTP1B D/A adipocytes,
resolved using SDS-PAGE, and then immunoblotted with anti-
phosphotyrosine antibodies. Upon insulin stimulation, two
prominent hyperphosphorylated bands at 60 and 160 kDa
were detected corresponding to “trapped” putative PTP1B sub-
strates (Fig. 1A, arrowheads). Lysis under stringent conditions
(radioimmunoprecipitation assay buffer) significantly attenu-
ated tyrosine phosphorylation, likely because of disruption of
PTP1B D/A-substrates coassociation. Proteins were stained
PTP1B Regulates PKM2 Tyrosine Phosphorylation
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using Coomassie Blue, and then the 60-kDa band was excised
and analyzed by mass spectroscopy. This led to the identifica-
tion of knownPTP1B substrates, such as cortactin (35), indicat-
ing the validity of this approach. In addition, several novel puta-
tive substrates were identified, among which was pyruvate
kinase.
PTP1B Regulates PKM2 Tyrosine Phosphorylation—Initially,
we examined the expression of the M1 splice isoform (PKM1)
of the PKM gene and M2 isoform (PKM2) in brown (21) and
white (3T3-L1) adipose cell lines. Immunoblot analyses
revealed the expression of both PKM1 and PKM2 in preadi-
pocytes and adipocytes (differentiation days 4, 10, and 18) (Fig.
1B). Because mass spectroscopy identified peptides that are
common to PKM1 and PKM2, we investigated the coassocia-
tion of each isoform with PTP1B. PTP1B was immunoprecipi-
tated from starved or insulin-stimulated PTP1B WT- and
PTP1BD/A-reconstituted adipocytes (21), resolved using SDS-
PAGE, and then immunoblotted with PKM1- and PKM2-spe-
cific antibodies (Fig. 1C). Significant coassociation of PTP1B
D/A with PKM1 and PKM2 was observed in adipocytes upon
insulin stimulation. Given the reported regulation of PKM2 by
tyrosine phosphorylation (28), and because PKM2 appears to
be the major isoform in adipocytes (Fig. 3), we further investi-
gated PKM2-PTP1B interaction. We reasoned if PKM2 is a
PTP1B target, then PTP1B deficiency should lead to increased
PKM2 tyrosine phosphorylation. To test this, PKM2 was
immunoprecipitated from starved or insulin-stimulated KO
and reconstituted (WT and D/A) adipocytes and then immu-
noblotted with anti-phosphotyrosine antibodies. PKM2 total
tyrosine phosphorylation was elevated significantly in KO and
D/A compared with WT adipocytes under basal and insulin-
stimulated conditions (Fig. 1D). PKM2 is inhibited by phosphory-
lation at Tyr-105 by oncogenic forms of fibroblast growth factor
receptor type 1 (28). Notably, PKM2 Tyr-105 phosphory-
lation was elevated significantly in KO and D/A compared with
WT adipocytes (Fig. 1D). In addition, we determined PKM2
tyrosine phosphorylation in interscapular BAT of control (fl/fl)
and adipose-specific PTP1B KO (AdPTP1B-KO) mice.
AdPTP1B KO mice fed chow or an HFD exhibited increased
PKM2 Tyr-105 phosphorylation compared with control mice
(Fig. 1E). Together, these data demonstrate elevated both total
and Tyr105 phosphorylation of PKM2 upon PTP1B deficiency
in adipocytes and in vivo suggesting that PTP1Bplays an impor-
tant role in regulating PKM2 activity.
Mapping of PKM2-PTP1B Interaction—Elevated PKM2
tyrosine phosphorylation upon PTP1B deficiency prompted us
FIGURE 1. Pyruvate kinase is a PTP1B substrate. A, immunoblot analyses (Blot) of phosphotyrosine proteins in PTP1B immunoprecipitates from PTP1B D/A
adipocytes starved or stimulated with insulin for 10 and 30min. Cells were lysed in Nonidet P-40 or radioimmunoprecipitation assay buffer (RIPA), and PTP1B
was immunoprecipitated (IP) using anti-human PTP1B antibodies (FG6) and immunoblotted using antibodies for phosphotyrosine. Arrowheads indicate
hyperphosphorylated proteins. B, immunoblot analyses of PKM2, PKM1, and tubulin in lysates of brown and 3T3-L1 adipocytes at days 0, 4, 10, and 18 of
differentiation. C, PTP1B was immunoprecipitated using FG6 antibodies from starved and insulin-stimulated PTP1BWT and D/A adipocytes (lysed in Nonidet
P-40) and then immunoblotted using antibodies for PKM2 and PKM1. D, PKM2 was immunoprecipitated from lysates of PTP1B KO adipocytes and KO
adipocytes reconstituted with PTP1BWT or PTP1B D/A and then immunoblotted using antibodies for phosphotyrosine, PKM2 (Tyr-105), and PKM2. Total cell
lysates were blotted for PTP1B and tubulin. The bar graph represents normalized data for pTyr/PKM2 and PKM2 (Tyr-105)/PKM2, and data are presented as
meansS.E. *, significantdifferencebetweenbasal and insulin-stimulated conditions for each cell type; #,p0.05; ##,p0.01, significantdifferencebetween
WT versus KO and D/A cells for the same treatment. E, immunoblot analyses of PKM2 (Tyr-105) and PKM2 in lysates of interscapular BAT of control (fl/fl) and
adipose-specific PTP1B KO (AdPTP1B-KO) mice fed regular chow (upper panel) or an HFD (lower panel) for 30 weeks. A.U., arbitrary unit.
PTP1B Regulates PKM2 Tyrosine Phosphorylation
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to investigatewhether PKM2 is a direct substrate of PTP1B.We
examined the subcellular localization of PTP1B D/A and
PKM2. GFP-tagged PTP1B D/A was transiently expressed in
preadipocytes, and colocalization with endogenous PKM2 was
monitored using confocal microscopy (Fig. 2A). Consistent
with previous reports, PTP1BD/A localized to the endoplasmic
reticulum network (11–13). Importantly, a subfraction of
endogenous PKM2 colocalized with PTP1B. In addition, bio-
chemical studies were performed to determine PTP1B-PKM2
coassociation. To that end, lentiviral shRNA was used to gen-
erate 3T3-L1 preadipocytes with stable knockdown of PKM
(sh-PKM) as described under “Experimental Procedures.”
Knockdown cells were reconstituted with non-targetable
(shRNA-resistant) cDNA encoding mouse PKM2 WT, K433E
mutant, and tyrosine (Y)-to-phenylalanine (F) mutants of indi-
vidual PKM2 tyrosines (Fig. 2B). PTP1B D/A was transiently
expressed in the generated cell lines and then immunoprecipi-
tated, and coassociation with PKM2 was determined. Consis-
tent with the proposed hypothesis, coassociation of PKM2WT
and PTP1B D/A was observed (Fig. 2C, first lane). Treatment
with pervanadate, a strong inhibitor of tyrosine phosphatases
that, as a phosphate mimetic, localizes at the catalytic pocket
and oxidizes the essential cysteinyl residue in the catalytic cen-
ter of the enzyme (36), disrupted PKM2-PTP1B D/A associa-
tion (Fig. 2C, second lane). This suggested that the association is
consistent with enzyme-substrate interaction that is mediated
by the active site of PTP1B.Of note, PKM2K433E (which atten-
uated total tyrosine phosphorylation) (28) exhibited minimal
coassociation with PTP1B D/A (Fig. 2C). Strikingly, mutation
of single tyrosine residues Tyr-105 or Tyr-148 nearly abolished
PKM2-PTP1B D/A coassociation, whereas mutations of other
tyrosine residues did not significantly alter coassociation (Fig.
2, C and D). No association was observed between PKM2 and
PTP1B WT, indicating that like many of its substrates, PTP1B
WT does not form a stable complex with PKM2 (data not
shown). Collectively, these data demonstrate that PKM2 is a
FIGURE 2.Mapping PKM2-PTP1B sites of interaction. A, immunostaining for PTP1B D/A (green), PKM2 (red), and nuclear DNA (blue) in preadipocytes. Cells
were visualized by fluorescence confocal microscopy. Scale bar 20 m. B, schematic depicting PKM2 domains and tyrosine sites. C, PKM2 knockdown cells
were reconstitutedwith PKM2WT, K433E, andY/Fmutants, and cell linesweregenerated. PTP1BD/Awas transiently expressed, immunoprecipitated (IP) using
FG6 antibodies, resolved using SDS-PAGE, and then immunoblotted (Blot) for PKM2. Membranes were reprobed for PTP1B and FLAG tag (expressed by
exogenous cDNA encoding PKM2WT and mutants). D, immunoblots of PKM2, FLAG, PTP1B, and tubulin in total cell lysates.
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direct substrate of PTP1B and that the Y105F and Y148F
mutants disrupt PKM2-PTP1B D/A association significantly.
Tyrosine Phosphorylation Regulates Adipose PKM2 Activity—
To investigate the role of PKM2 Tyr-105 and Tyr-148 in regu-
lating adipose PKM2 activity, we utilized 3T3-L1 preadipocytes
with stable knockdown of PKM2. Control preadipocytes were
generated using a scramble shRNA (sh-SCR). To rule out off-
target effects, knockdown cells were reconstituted with non-
targetable cDNA encoding mouse PKM2 WT (M2R). In addi-
tion, parallel knockdown cells were reconstituted with the
Y105F andY148Fmutants. Immunoblot analysis demonstrated
a significant decrease in PKM2 expression in knockdown cells
(Fig. 3A). Although the shRNA targeted a region common to
PKM1 and PKM2, PKM1 protein levels did not decrease as
much as PKM2 protein levels, perhaps because of PKM1 being
a more stable protein. An antibody that equally recognizes
PKM1 and PKM2 revealed a significant decrease in total PKM
in knockdown cells (Fig. 3A), indicating that PKM2 accounts
for the majority of pyruvate kinase in adipocytes. Consistent
with this idea, total pyruvate kinase activity decreased in
response to knockdown of PKM2 and was rescued by reconsti-
tution of PKM2 (Fig. 3,C andD). Immunoblot analysis revealed
significant attenuation of PKM2 Tyr-105 phosphorylation in
knockdown cells (Fig. 3, A and B). As expected, Tyr-105 phos-
phorylation was attenuated in Y105F adipocytes, whereas
Y148F adipocytes revealed increased Tyr-105 phosphorylation
compared with control adipocytes. In addition, PKM2 knock-
down cells exhibited a 60.8 0.8% decrease in pyruvate kinase
activity, whereas preadipocytes reconstituted with WT (M2R)
or Y105F exhibited comparable activity to controls (Fig. 3, C
andD). On the other hand, Y148F-reconstituted preadipocytes
exhibited significant attenuation of pyruvate kinase activity
consistent with their elevated Tyr-105 phosphorylation. Com-
parable pyruvate kinase activity was also observed in differen-
FIGURE 3. Tyrosine phosphorylation of PKM2 regulates its activity. Immunoblot analyses of PKM2 (Tyr-105), PKM2, PKM1, PKM1/2, and tubulin in 3T3-L1
preadipocytes expressing shRNA targeted to PKM (sh-PKM) or a scrambled (SCR) control and knockdown cells reconstituted withWT (M2R), Y105F, and Y148F
mutants. B, the bar graph represents normalized data for PKM2 (Tyr-105)/PKM2 andpresented asmean S.E. *, p 0.05 and **, p 0.01, significant difference
between different cells versus control (sh-SCR). A.U., arbitrary unit. C, total pyruvate kinase activity in sh-PKM, sh-SCR, and knockdown preadipocytes reconsti-
tutedwithPKM2WT (M2R) ormutants (Y105FandY148F). Cellswere treatedwithPTP1B inhibitor (CII), and total pyruvate kinaseactivitywasdetermined (dotted
lines).D, thebar graph represents normalizeddata for pyruvate kinase activity (amount of-NADHconsumedusing1gof protein from total cell lysates/1min
of enzymatic reaction) and presented as mean S.E. from two independent experiments. *, p 0.05 and **, p 0.01, significant difference between PTP1B
inhibitor-treated versus non-treated for each cell type; #, p 0.05; ##, p 0.01, significant difference between control (sh-SCR) versus other cells for the same
treatment.
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tiated adipocytes (supplemental Fig. S1A). To further establish
regulation of PKM2 phosphorylation and activity by PTP1B,
preadipocytes were treated with PTP1B inhibitor (CII) as
described under “Experimental Procedures.” CII decreased
PTP1B activity by 69.7  5.4% and increased PKM2 Tyr-105
phosphorylation (supplemental Fig. S1, B and C). Notably, CII
significantly decreased total pyruvate kinase activity in control
(sh-SCR) and Y148F cells (Fig. 3, C and D). M2R cells treated
withCII exhibited a trend for decreased pyruvate kinase activity
but did not reach statistical significance, whereas knockdown
andY105FCII-treated cells exhibited comparable activity tonon-
treated cells (Fig. 3, C and D). Together, these data are consist-
ent with previous findings that PKM2 tyrosine phosphory-
lation at Tyr-105 inhibits its pyruvate kinase activity.
Adipose PKM2 Tyr-105 Phosphorylation Is Regulated
Nutritionally—To investigate whether adipose PKM2 phos-
phorylation is nutritionally regulated in vivo, we determined the
effects of high-fat feeding on Tyr-105 phosphorylation in various
adipose tissue depots. Mice were fed regular chow diet or a HFD
(60% kcal from fat) starting at 7 weeks of age and then sacrificed
after 3, 7, and 11 weeks. Immunoblot analyses revealed compara-
ble PKM2Tyr-105 phosphorylation inmice fed regular chow diet
at 3 and 11weeks in all examined adipose depots (Fig. 4). Notably,
high-fat feeding for 3 weeks significantly attenuated PKM2 Tyr-
105 phosphorylation in subcutaneous and epididymal depots (Fig.
4, B,C, and F). Prolonged high-fat feeding (7 and 11 weeks) led to
significant attenuation of PKM2 Tyr-105 phosphorylation in all
examined adipose depots, and this correlated with increased
PTP1B expression (Fig. 4). In line with these biochemical studies,
immunostaining of adipose tissue sections revealed comparable
results with PKM2 Tyr-105 phosphorylation decreasing upon
prolonged high-fat feeding (supplemental Fig. S2). Of note, HFD-
induced attenuation of PKM2 Tyr-105 phosphorylation corre-
lated with decreased insulin receptor (IR) (Tyr-1162/Tyr-1163)
phosphorylation and decreased Akt (Ser-473) phosphorylation in
adipose depots upon HFD feeding (supplemental Fig. S3).
Decreased IRandAktphosphorylation indicatesdecreased insulin
sensitivity in HFD-fed mice compared with those fed chow.
Together, these data demonstrate that adipose PKM2 Tyr-105
phosphorylation is regulated nutritionally and correlates with the
development of insulin resistance in HFD-fedmice.
FIGURE 4. Regulation of adipose PKM2 Tyr-105 phosphorylation by high-fat feeding. Immunoblot analyses of PKM2 (Tyr-105), PKM2, PTP1B, and tubulin
in lysates of brown (A), subcutaneous (S.Q.) (B), epididymal (Epi.) (C), mesenchymal (Mes.) (D), and retroperitoneal (Ret.) (E) adipose tissue depots of mice fed
chow or an HFD for the indicated times. Each lane represents a sample from a separate animal. F, the bar graph represents normalized data for PKM2
(Tyr-105)/PKM2 presented as mean S.E. *, p 0.05 and **, p 0.01, significant difference between all groups versus mice fed a chow diet for 3 weeks; #,
significant difference between mice fed an HFD for 7 and 11 weeks versusmice fed a HFD for 3 weeks.
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Adipose PKM2 Tyr-105 Phosphorylation Correlates with Sys-
temic Metabolic Status—We investigated whether adipose
PKM2 Tyr-105 phosphorylation directly correlates with an
altered metabolic state (independently of HFD-induced obe-
sity) and whether this is conserved among species. To that end,
we utilized different experimental models including rats, non-
human primates, and human subjects who were subjected to
different interventions that altered their metabolic state.
Firstly, we used UCD-T2DM diabetic rats, which exhibit adult
onset polygenic obesity and insulin resistance and subsequently
develop type 2 diabetes (37). Leptin administration to diabetic
UCD-T2DMrats normalizes fasting plasma glucose concentra-
tions and markedly improves insulin sensitivity independently
of food intake (38). Diabetic UCD-T2DM rats received leptin
(murine recombinant, 0.5 mg/kg) or saline injections (control).
Importantly, saline-injected animals were pair-fed to the lep-
tin-treated animals to control for food intake, and tissues were
collected after one month of treatment. Immunoblot analyses
revealed increased PKM2 Tyr-105 phosphorylation in white
adipose tissue of the leptin-treated rats comparedwith controls
(Fig. 5A). Consistent with the improved insulin sensitivity in
leptin-treated rats (38), they exhibited increased IR and Akt
phosphorylation compared with controls (supplemental Fig.
S4A). Thus, adipose PKM2 Tyr-105 phosphorylation increases
upon improved systemic insulin sensitivity independently of
significant alterations in body weight.
Next, we investigated the regulation of PKM2 Tyr-105 phos-
phorylation in a non-human primate model of insulin resis-
tance, fructose-fed rhesus macaques (39). Base-line adipose
samples were collected (Control), and animals were divided
into two groups: one fed fructose (Fructose) and another fed
fructose supplemented with fish oil (Fructose  F. Oil) for 6
FIGURE 5. Adipose PKM2 Tyr-105 phosphorylation correlates with systemic metabolic status. A, immunoblot analyses of PKM2 (Tyr-105) and PKM2 in
adipose tissue lysates from leptin-treated and non-treated (Control) UCD-T2DM diabetic rats. The bar graph represents normalized data for PKM2 (Tyr-105)/
PKM2 and presented asmeans S.E. **, p 0.01, significant difference between leptin-treated and control rats. A.U., arbitrary unit. B, immunoblot analyses of
PKM2 (Tyr-105) andPKM2 in adipose tissue lysates from rhesusmonkeys thatweremonitored for 6months (Control) and thendivided into twogroups: one fed
fructose (Fructose) and the other fed fructose supplemented with fish oil (Fructose F. Oil) for 6 months. The bar graph represents normalized data for PKM2
(Tyr-105)/PKM2, and data are presented as mean S.E. **, p 0.01, significant difference between chow (Ctr.) versus fructose diets; ##, p 0.01, significant
difference between fructose (Fruct.) versus fructose with fish oil (Fruct F. Oil) diets. C, immunoblots of PKM2 (Tyr-105) and PKM2 in lysates of subcutaneous
adipose tissue biopsies from human subjects before and after consuming 25% of energy requirements as fructose-sweetened (upper panel) or glucose-
sweetened (lower panel) beverage for 10 weeks. Subjects were separated into two groups: body mass index 30 and body mass index 30. The bar graph
represents normalizeddata for PKM2 (Y105)/PKM2andpresentedasmeanS.E. **,p0.01, significant differencebetween the same subjects before andafter
fructose-sweetened beverage consumption.
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months as detailed under “Experimental Procedures.” Animals
fed fructose progressively developed glucose intolerance and
decreased insulin sensitivity (39). Immunoblot analyses of sub-
cutaneous adipose tissue revealed that PKM2 Tyr-105 phos-
phorylation was decreased significantly in the fructose-fed
group compared with controls (Fig. 5B). On the other hand, the
animals supplemented with fish oil exhibited PKM2 Tyr-105
phosphorylation that was comparable with controls. In addi-
tion, PKM2 Tyr-105 phosphorylation correlated with IR and
Akt phosphorylation, which decreased in the fructose-fed
group compared with controls and increased with fish oil sup-
plementation (supplemental Fig. S4B).
Lastly, to determine whether findings from these animal
models translate to humans, we analyzed PKM2 Tyr-105 phos-
phorylation in human subcutaneous adipose tissues from sub-
jects that developed insulin resistance while consuming fruc-
tose-sweetened beverages. Subjects were provided 25% of
energy requirements from glucose- or fructose-sweetened bev-
erages for 10weeks. Subjects consuming fructose, but not those
consuming glucose beverages, exhibited increased fasting
plasma glucose and decreased insulin sensitivity (40). Immuno-
blot analyses of subcutaneous adipose tissue in fructose-fed
overweight (body mass index  30) or obese (body mass
index 30) subjects exhibited decreased PKM2 Tyr-105 phos-
phorylation after fructose feeding (Fig. 5C). In contrast,
Tyr-105 phosphorylation did not change significantly in subcu-
taneous adipose tissue samples from subjects consuming glu-
cose-sweetened beverages (Fig. 5C). Collectively, these results
demonstrate that adipose PKM2 Tyr-105 phosphorylation
directly correlates with the metabolic state in different species.
Whether alterations in Tyr-105 phosphorylation are causative
or consequences of the metabolic state remain to be
determined.
DISCUSSION
The coordinated actions of protein tyrosine phosphatases
and protein tyrosine kinases regulate phosphotyrosine-medi-
ated signaling under physiological and pathophysiological con-
ditions. Understanding the dynamicmodulation of phosphoty-
rosine signaling in adipose tissue may provide avenues for
therapeutic intervention inmetabolic diseases. In this study, we
identified PKM2 as a novel PTP1B substrate in adipocytes and
adipose depots in vivo and determined PKM2 Tyr-105 and
Tyr148 as key residues that mediated the interaction. In addi-
tion, we demonstrated regulation of PKM2 pyruvate kinase
activity in adipocytes by tyrosine phosphorylation. Further, we
uncovered direct correlation of adipose PKM2 Tyr-105 phos-
phorylation with the systemic metabolic state in rodents, non-
human primates, and humans. Collectively, these findings pro-
vide new insights into the regulation of adipose PKM2 by
tyrosine phosphorylation and its metabolic function.
Several lines of evidence established PKM2 as a novel PTP1B
substrate. First,mass spectrometry of adipocytes expressing the
PTP1B-trapping mutant identified PKM as a PTP1B-interact-
ing protein. Second, adipocytes and adipose tissue lacking
PTP1B exhibited increased PKM2 total and Tyr-105 phos-
phorylation. Third, substrate trapping demonstrated a direct
association between PKM2 and PTP1B D/A. Importantly, per-
vanadate treatment disrupted PKM2-PTP1B D/A association,
indicating that it is consistent with enzyme-substrate interac-
tion that is mediated by the PTP1B active site. Fourth, pharma-
cological inhibition of PTP1Bwith a PTP1B-specific small mol-
ecule inhibitor (CII) increased PKM2Tyr-105 phosphorylation
and attenuated pyruvate kinase activity. At the molecular level,
we identified PKM2 Tyr-105 and Tyr-148 as key residues that
mediate interaction with PTP1B. However, the residue that
serves as the primary interaction site remains to be delineated.
The observed disruption of PTP1B D/A-PKM2 Y148F interac-
tion (Fig. 2), despite increased Tyr-105 phosphorylation in
Y148F-expressing adipocytes (Fig. 3), indicates that Tyr-148 is
important for binding of PKM2 to PTP1B. Of note, PKM2
Y105F mutation also disrupts PTP1B D/A-PKM2 interaction
(Fig. 2). In addition to adipose tissue, PKM2 is expressed in
other differentiated tissues such as lung, retina, pancreatic
islets, and proliferating cells (such as embryonic cells, adult
stem cells, and especially tumor cells) (25, 41). Further studies
are required to determine whether PKM2 and PTP1B interact
in other tissue(s). Indeed, both PTP1B (42) and PKM2 are
expressed in pancreatic islets, and preliminary studies suggest
coassociation in pancreatic lysates5. PTP1B-catalyzed dephos-
phorylation of its substrates is regulated, at least in part, by its
subcellular location on the cytoplasmic face of the endoplasmic
reticulum, which imposes topological constraints (11, 43).
Thus, endoplasmic reticulum-bound PTP1B can access and
dephosphorylate cytosolic PKM2 but presumably not other
pools, such as nuclear PKM2. Several studies report PKM2
nuclear translocation and demonstrate a role in activating gene
transcription and cell proliferation (44–47). It is possible that
other protein tyrosine phosphatase(s) may also target PKM2 at
various subcellular locations, including the nucleus. Overall,
although additional studies are needed to dissect the spatial and
temporal regulation of PKM2-PTP1B interaction and uncover
other candidate PTPs, these studies are the first to identify a
protein tyrosine phosphatase that directly regulates PKM2
tyrosine phosphorylation and activity.
PKM2 tyrosine phosphorylation regulates its pyruvate kinase
activity in adipocytes. Using an in vitro adipocyte cell systemwe
demonstrated a direct effect of Tyr-105 phosphorylation on
PKM2 activity (Fig. 3). Indeed, PKM2 Y148F adipocytes exhib-
ited increased Tyr-105 phosphorylation and significant attenu-
ation of PKM2 pyruvate kinase activity. This is consistent with
previous findings that PKM2 tyrosine phosphorylation at Tyr-
105 inhibits its pyruvate kinase activity (28). Notably, PTP1B
deficiency or inhibition in adipocytes increased PKM2 Tyr-105
phosphorylation. The precise contribution of adipose PKM2
tyrosine phosphorylation tometabolic regulation remains to be
determined. However, this study clearly demonstrated attenu-
ation of PKM2Tyr-105 phosphorylation in BAT andwhite adi-
pose tissue depots with prolonged high-fat feeding inmice con-
comitantwith increased PTP1B expression in these depots (Fig.
4). Importantly, elevated PKM2 Tyr-105 phosphorylation cor-
relatedwith increased insulin sensitivity anddecreasedTyr-105
phosphorylation correlated with insulin resistance in rodents,
5 A. Bettaieb and F. G. Haj, unpublished data.
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non-human primates, and humans. Additional studies are war-
ranted to delineate the role of adipose PKM2 in metabolic reg-
ulation and to determine whether alterations in PKM2Tyr-105
phosphorylation are causative or a consequence of the meta-
bolic state in vivo.
The metabolic functions of adipose PTP1B are unresolved,
with studies demonstrating detrimental, beneficial, or no
effects of adipose PTP1B deficiency on body mass regulation
and insulin sensitivity. Antisense oligonucleotides that lower
PTP1B levels only in adipose tissue and liver reduce diet-in-
duced obesity and enhance insulin signaling in obese (ob/ob)
and diabetic (db/db) mice (48, 49). Similarly, administration of
PTP1B antisense oligonucleotides to monkeys reduces PTP1B
in adipose tissue and liver and improves insulin sensitivity (50).
The observed effects could reflect a loss of PTP1B in liver
and/or adipose tissue. On the other hand, adipose-specific
PTP1BKOmice generated using the adipocyte protein 2 (aP2)-
promoter to drive Cre recombinase expression exhibit
increased body weight when fed an HFD (19). However, if the
observed weight gain is caused only by adipose-specific PTP1B
deficiency remains to be determined because the aP2 promoter
can delete the target gene in other cell types (51, 52). Indeed,
adipose-specific PTP1B KO mice generated using the adi-
ponectin promoter exhibit comparable body weight to controls
when fed an HFD but display larger adipocytes and increased
basal lipogenesis (20). These studies identify PKM2 as one of
several PTP1B substrates that can mediate PTP1B functions in
adipose tissue. Presumably PTP1B can engage different sub-
strate(s) in adipocytes, depending, at least in part, on the nature
of the challenge/stimulus and its magnitude and duration.
Intriguingly, adipose PTP1B function could vary, depending on
the adipose depot. PTP1B inhibition in 3T3-L1 adipocytes
inhibits adipogenesis (53). In contrast, PTP1B deficiency in
brown adipocytes promotes differentiation and adipogenesis
(21, 54).
The salutary effects of PTP1B deficiency and inhibitionmake
it a therapeutic target for obesity, type 2 diabetes, and some
types of cancer (55, 56). In addition, PKM2 plays important
roles in cancer cells signaling and metabolism and is proposed
as an attractive therapeutic target. PKM2 deficiency or inhibi-
tion elicits anticancer effects, such as impairment of cancer
growth, induction of cell death, and increased sensitivity to
chemotherapy (27, 57–59).On the other hand, compounds that
activate PKM2 catalytic function may also have therapeutic
implications to suppress tumorigenesis (60–62). The regula-
tion of PKM2 activity in adipose tissue by tyrosine phosphory-
lation as presented here highlights the need to evaluate PKM2
functions in normal tissues before inhibitors and activators are
deployed for therapeutic interventions. Dissecting the intracel-
lular signaling events elicited by PTP1B and PKM2 will likely
yield valuable insights and may lead to new avenues for thera-
peutic intervention.
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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1: Regulation of pyruvate kinase activity by tyrosine phosphorylation. Total pyruvate kinase activity in 
differentiated  3T3-L1 adipocytes expressing shRNA targeted to PKM (sh-PKM) or a scrambled (SCR) control and 
knockdown cells reconstituted with WT (M2R), Y105F and Y148F mutants. Bar graph represents normalized data for 
pyruvate kinase activity and presented as means ± SEM from two independent experiments. (*) indicates significant 
difference between control (sh-SCR) versus other cells. B) 3T3-Ll preadipocytes treated were with PTP1B inhibitor 
(CII; 200 nM) for 12 h and PTP1B activity was determined. (*) indicates significant difference between treated and 
untreated cells. C)  Immunoblots of PKM2 (Tyr105), PKM2 and Tubulin in lysates of sh-PKM and sh-SCR 
preadipocytes without (-) or with (+) PTP1B inhibitor treatment. 
 
Figure S2: Immunostaining of PKM2 and Tyr105 in adipose depots. Brown (BAT), epidydimal (Epi.) and 
mesenchymal (Mes.) adipose sections of wild type male mice fed regular chow or HFD for 3 and 11 weeks were 
immunostained using PKM2 and Tyr105 antibodies. 
 
Figure S3: Decreased IR and Akt phosphorylation in adipose depots of mice fed HFD. Immunoblots of pIR 
(Y1162/Y1163), IR, pAkt (S473), and Akt in lysates of (A) brown (BAT), (B) subcutaneous (S.Q.), (C) epididymal 
(Epi.), (D) mesenchymal (Mes.), and (E) retroperitoneal (Ret.) adipose tissue depots of mice fed chow or HFD for the 
indicated times. Each lane represents a sample from a separate animal. Bar graphs represent normalized data for pIR 
(Y1162/Y1163)/IR (F) and pAkt (S473)/Akt (G) presented as means ± SEM. (*) indicates significant difference 
between all groups versus mice fed chow diet for 3 weeks, (#) indicates significant difference between mice fed HFD 
for 7 and 11 weeks versus mice fed HFD for 3 weeks.  
 
Figure S4: IR and Akt phosphorylation in adipose tissue of rats and rhesus monkeys. A) Immunoblots of pIR 
(Y1162/Y1163), IR, pAkt (S473) and Akt in lysates of adipose tissues from leptin treated and non-treated UCD-T2DM 
diabetic rats. Bar graphs represent normalized data for pIR (Y1162/Y1163)/IR and pAkt (S473)/Akt, and presented as 
means ± SEM. (*) indicates significant difference between leptin treated and control rats. B) Immunoblots of pIR 
(Y1162/Y1163), IR, pAkt (S473) and Akt in lysates of adipose tissues from rhesus monkeys that were divided into two 
study groups; one fed fructose (Fructose) and the other fed fructose supplemented with fish oil (Fructose + F. Oil) for 6 
months. Bar graphs represent normalized data for pIR (Y1162/Y1163)/IR and pAkt (S473)/Akt and presented as means 
± SEM. (*) indicates significant difference between chow (Ctr.) and fructose diets. (#) indicates significant difference 
between fructose (Fruct.) and fructose with fish oil (Fruct + F. Oil) diets. 
 




